Corvus Pharmaceuticals at Jefferies Conference: Advancing Socolitinib Trials

Corvus Pharmaceuticals presented at the Jefferies Global Healthcare Conference, highlighting the progress of socolitinib, an ITK inhibitor, currently in Phase 3 trials for peripheral T-cell lymphoma and Phase 1 trials for atopic dermatitis. Early atopic dermatitis trial data showed a dose-dependent reduction in EASI scores, with the 200mg BID cohort demonstrating a 64.8% mean reduction and significant improvement in pruritus, prompting an extension cohort to assess longer treatment duration; results from this extension cohort are expected in November 2025 as Corvus targets a potentially $30 billion market in atopic dermatitis.

Analysis

Corvus Pharmaceuticals (NASDAQ:CRVS) presented an optimistic update on its lead drug candidate, socolitinib, an ITK inhibitor, at the Jefferies Global Healthcare Conference. The company highlighted socolitinib's progression in a Phase 3 registration trial for peripheral T-cell lymphoma (PTCL) and promising results from its Phase 1 trial in moderate to severe atopic dermatitis (AD). Specifically for AD, the 200mg BID dose in Cohort 3 demonstrated a statistically significant mean EASI score reduction of 64.8% at 28 days (p=0.036) compared to 34.4% for placebo, with 50% of patients achieving EASI 75. Notably, new data revealed a dramatic improvement in pruritus within one week for this cohort, supported by changes in IL-31 biomarkers. Corvus is advancing socolitinib into an extension cohort for AD, treating patients for two months, with results anticipated in November 2025, to further evaluate its efficacy and durability. The company views socolitinib as a platform technology with broad applications, targeting a substantial $30 billion market in AD with a potentially safer, oral treatment, and benefits from composition of matter patents extending beyond 2040. While the clinical data and strategic outlook are encouraging, the presentation did not include financial updates, leaving some operational funding questions for future clarification. The drug's high selectivity for ITK, contrasted with less selective kinase inhibitors, is presented as a key advantage for its safety and efficacy profile across oncology and immune diseases.

Key Decisions for Investors

• Investors should closely monitor the upcoming results from socolitinib's Phase 1 atopic dermatitis extension cohort, expected around November 2025, as these will be critical for validating longer-term efficacy and safety.
• Consider the significant market potential for socolitinib in atopic dermatitis (estimated $30 billion) and peripheral T-cell lymphoma, alongside its promising early clinical data, strong patent protection beyond 2040, and unique mechanism of action when evaluating Corvus Pharmaceuticals.
• Track progress in the ongoing Phase 3 trial for peripheral T-cell lymphoma and the execution of the Phase 2 strategy for atopic dermatitis, as these are key de-risking milestones, while also seeking clarity on the company's financial runway to support these development programs in future disclosures.